Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

Catalyst Pharmaceuticals (CPRX) Gains from Sales and Divestitures (2016 - 2025)

Catalyst Pharmaceuticals' Gains from Sales and Divestitures history spans 5 years, with the latest figure at $333865.0 for Q4 2025.

For Q4 2025, Gains from Sales and Divestitures fell 8.5% year-over-year to $333865.0; the TTM value through Dec 2025 reached $333865.0, down 8.5%, while the annual FY2025 figure was $333865.0, 8.5% down from the prior year.
Gains from Sales and Divestitures reached $333865.0 in Q4 2025 per CPRX's latest filing, down from $364861.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $364861.0 in Q4 2024 to a low of $333865.0 in Q4 2025.